COHANCE

What Cohance Lifesciences promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q1 FY27

what the last two calls moved 24 tracked 2 delivered 9 missed 13 open
  • API Product Validations delivered said Q1 FY26 Promised: 7 to 8 new validations Q1 FY27: FY26 is complete. The target was achieved.
  • NJ Bio EBITDA Margin missed said Q2 FY25 Promised: 20%+ for CY25 onwards Q1 FY27: NJ Bio reported an adjusted EBITDA loss of INR328 million, confirming the target is not only missed but performance is deeply negative.
  • Total Revenue diluted said Q3 FY25 Promised: $1 billion by FY30 Q1 FY27: I do think we may be a little bit away from it over the next 3 to 4 years, but I would love to put more color to it before I can answer you.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 24 tracked commitments for Cohance Lifesciences — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens